Quantcast
Home > Quotes > CLRBW

Cellectar Biosciences, Inc. Warrants (CLRBW) Quote & Summary Data

CLRBW 
$0.12
*  
0.0692
136.22%
Get CLRBW Alerts
*Delayed - data as of Dec. 10, 2018  -  Find a broker to begin trading CLRBW now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 0.12 / $ 0.066
Share Volume
2,100
50 Day Avg. Daily Volume
N/A
Previous Close
$ 0.0508
52 Week High / Low
$ 0.7901 / $ 0.05
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
2,100
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $0.12 is 140.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.12 $ 0.7901
 Low: $ 0.066 $ 0.05

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugateTM (PDCsTM) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDCTM platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations. Our lead PDC candidate, CLR 131, provides targeted delivery of the cytotoxic (cell-killing) radioisotope iodine 131. CLR 131 is in a Phase 1 clinical study for relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a range of other B-cell malignancies.  ... More ...  

Nasdaq Official Price

Open Price:
$ 0.066
Open Date:
Dec. 10, 2018
Close Price:
$ 0.12
Close Date:
Dec. 10, 2018

Research Brokers before you trade

Want to trade FX?

Analyst Info